SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.

Shanghai Shyndec Pharmaceutical Co., Ltd.

600420

CNE000001JG2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 15/07/2024 BST			5-day change	1st Jan Change
12.49 ^CNY	+0.56%		+6.75%	+27.58%

07-12	Shyndec Pharma Unit Gets Rights for Ceftazidime Avibactam Sodium for Injection	MT
07-09	Shanghai Shyndec Pharmaceutical Obtains Drug Registration for Anti-Tumor Injection; Shares Jump 9%	MT

Shanghai Shyndec Pharmaceutical Co., Ltd. announced that it has received CNY 100 million in funding from a group of investors

January 05, 2017

On January 6, 2017, Shanghai Shyndec Pharmaceutical Co., Ltd. (SHSE:600420) closed the transaction. The company issued 3,441,156 shares at CNY 29.06 per share for gross proceeds of CNY 99,999,993.36. The company incurred issuance expenses of CNY 2,120,000 in the transaction. The transaction has been approved by the China Securities Regulatory Commission.

Latest news about Shanghai Shyndec Pharmaceutical Co., Ltd.

Shyndec Pharma Unit Gets Rights for Ceftazidime Avibactam Sodium for Injection	07-12	MT
Shanghai Shyndec Pharmaceutical Obtains Drug Registration for Anti-Tumor Injection; Shares Jump 9%	07-09	MT
Shyndec Pharma Unit Gets China Nod for Analgesic Ingredient	06-14	MT
Shyndec Pharma Unit Gets China Nod for Conjunctivitis Eye Drops	06-14	MT
China Grants Registration Approval for Shanghai Shyndec Pharmaceutical Unit's Flu Injection	05-15	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets	04-16	MT
China stocks rise after new guidelines; HK shares drop	04-15	RE
Chinese FDA Grants Marketing Approval for Shyndec Subsidiary's Drug Raw Materials	04-10	MT
China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator	03-27	MT
Shyndec Pharma's Unit Gets Regulatory Nod for Sheep Vaccine	03-07	MT
Shyndec Pharma Unit's Cefotaxime Sodium for Injection Passes Drug Regulator's Consistency Evaluation	02-21	MT
Cancer Drug of Shyndec Pharma's Unit Passes Drug Regulator's Evaluation	02-20	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	01-25	CI
Shyndec Pharma Unit Obtains Antihistamine Marketing Rights for 7.7 Million Yuan	01-03	MT
China Grants Supplementary Drug Approval for Shyndec Pharmaceutical Subsidiaries' Antibiotic, Hypertension Tablets	12-08	MT
Shyndec Pharma Passes Drug GMP Compliance Inspection	11-28	MT
Shyndec Pharmaceutical's Drug Chosen for China's Centralized Bid	11-08	MT
Shyndec Pharmaceutical Unit's Cefprozil Tablets Passes Regulatory Evaluation	11-07	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	26/10/23	CI
Shyndec Pharmaceutical's Unit Gets Nod for Lidocaine Hydrochloride's Listing	19/09/23	MT
Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) added to S&P Global BMI Index	18/09/23	CI
Shanghai Shyndec Pharma Gets Nod to Market Blood Sugar Drug Ingredient	14/09/23	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	24/07/23	CI
Shyndec Pharmaceutical's Unit Gets Nod for Registration of Oprinone Hydrochloride Injection	06/07/23	MT

Chart Shanghai Shyndec Pharmaceutical Co., Ltd.

Duration

Period

Chart Shanghai Shyndec Pharmaceutical Co., Ltd.

More charts

Company Profile

SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.

Sector

Pharmaceuticals

Calendar

28/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

12.49

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+27.58%	2.31B
MERCK KGAA	+6.25%	72.87B
KYOWA KIRIN CO. LTD.	+34.09%	10.31B
YUHAN CORPORATION	+40.84%	5.23B
SK BIOPHARMACEUTICALS CO., LTD.	-18.53%	4.62B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+12.65%	3.52B
BETTA PHARMACEUTICALS CO., LTD.	-39.96%	1.78B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-45.87%	1.69B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B
SUPERNUS PHARMACEUTICALS, INC.	0.00%	1.59B

Specialty & Advanced Pharmaceuticals